Antibiotic resistance is a bacterial defense mechanism against antibiotics. It can rapidly spread from one bacterium to another. This makes antibiotics increasingly ineffective.
Detailed description
The level of resistances against antibiotics is rising. This is a great challenge for physicians and scientists. Scientists within the DZIF research field “Healthcare-associated and Antibiotic-resistant bacterial Infections” aim to develop new strategies against the development and spread of resistance.
Many bacteria produce substances to gain an advantage over competitors in their highly competitive natural environment. Researchers at the University Hospital Bonn (UKB), the University of Bonn and
Please use this image only in connection with this press release.
Antibiotic resistance is one of the challenges facing mankind in the 21st century. This includes antibiotic-resistant tuberculosis. Just in time for World Tuberculosis Day on 24 March 2024, the
While tuberculosis (TB) has become relatively rare in Germany and other industrialised nations, around ten million people contract the bacterial infection every year, especially in resource-poorer
New active substances for the treatment of resistant bacteria are needed more urgently than ever – yet only few candidates make the leap from research to clinical application. To facilitate precisely
Tuberculosis and malaria are among the deadliest infectious diseases worldwide and are increasingly spreading, not least due to climate change. In both cases, antimicrobial resistance renders
A recent clinical study shows that ganfeborole could be a promising candidate for the safe and effective treatment of pulmonary tuberculosis. Using microbiological testing and innovative imaging
BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug
Tuberculosis is currently the infectious disease that causes the most deaths worldwide. Of particular concern is the increasing emergence of multidrug-resistant tuberculosis bacteria, particularly in
INCATE (the INCubator for Antibacterial Therapies in Europe) and Kineticos AMR Accelerator Fund I (KAMRA I), have announced the beginning of a new collaboration that aims to enhance the support for
